MangoceuticalsNASDAQ: MGRX

Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Acceptance for Australian Patent Application No. 2020235666, which is the National Phase of International Application No. PCT/US2020/022903.

Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Allowance for Japanese Patent Application No. 2021-545824, originally applied for by Intramont Technologies, Inc. (“Intramont”).

Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that its subsidiary, MangoRx Mexico S.A. de C.V. (“MangoRx Mexico”), in conjunction with its Mexico-based pharmacy partner Emifarma S.A. de C.V (“Emifarma”), has successfully completed its first sample batch of Mango ED oral dissolvable tablets (ODTs) specifically to be marketed and sold in Mexico and other eligible Latin American (LATAM) countries.

Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, hormone replacement therapies and weight loss is excited to announce that it has engaged renown international performance marketing company, Crakmedia to champion the Company's ongoing creative and digital marketing initiatives.

Mangoceuticals, Inc. (NASDAQ: MGRX) announced significant growth in revenue and customer acquisition in the first quarter of 2024 compared to the same period in 2023. The company reported a 108% increase in sales, reaching $214,000 USD, up from approximately $100,000 USD in the first quarter of 2023, indicating positive financial performance in Q1 2024.

Mangoceuticals (NASDAQ: MGRX ) stock is dropping on Friday after the men's wellness products company launched a stock offering this morning. That stock offering has the company selling 5 million shares of MGRX stock.

Shares of Mangoceuticals Inc. MGRX, +10.81% fell 6.7% in premarket trading, to extend their sharp pullback from the previous session's intraday high. The stock had rocketed as much as 60.8% to an intraday high of $2.38 soon after Thursday's open, but closed up just 10.8%, after the erectile dysfunction (ED) drug maker announced a sponsorship deal with Barstool Sports.

Shares of Mangoceuticals Inc. MGRX, +14.86% skyrocketed as much as 60.8% intraday, before paring gains to be up 15.2% in very active afternoon trading, after the erectile dysfunction (ED) drug maker announced a sponsorship deal with Barstool Sports. Trading volume ballooned to 43.4 million shares, compred with the full-day average over the past 30 days of about 376,500 shares.

Use these tips for paying taxes when investing in penny stocks The post Trading Penny Stocks: Tips for Paying Taxes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.